Event-Driven Stocks

Foamix Pharmaceuticals Ltd.

Healthcare · Medicinal Chemicals & Botanical Products · L3 · SEC filings ↗ · Compare ⊕

Signs1 good5 warning1 severedetails ↓

Financials

SEC XBRL · annual
 FY19FY18FY17FY16FY15
Revenue$308,000$906,000$3.7M$5.5M$849,000
Operating income−$15.9M−$25.7M−$65.6M−$29.6M−$16.9M
Net income−$95.2M−$74.2M−$65.7M−$29.3M−$16.5M
Total assets$81.2M$103.7M$80.3M$135.6M
Total liabilities$63.6M$11.5M$11.7M$5.7M
Equity$17.6M$92.2M$68.6M$130.0M$100.8M
EPS (diluted)
Shares out.54.4M37.6M37.5M37.2M30.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2019
Operating margin
−5157.1%
Net margin
−30901.9%
Return on equity
−541.6%
Return on assets
−117.3%
Return on capital (ROCE)
−30.6%
Liabilities / assets
78.3%
Debt / equity
3.62×
Book value / share
$0.32
Revenue growth (YoY)
−66.0%
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2019
Altman Z″ (distress)
-9.69distress
Accruals / assets
26.8%clean
Piotroski F-Score
1/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
30
/ 100
Profitability 0Growth 0Catalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

1 severe5 warning1 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
0 acquisitions10 disposalsnet 429,879 shares · last 10
InsiderDateTypeSharesPrice
Stern StanleyDirectorMar 9, 2020D21,147
Wiley Matthew T.Officer — Chief Commercial OfficerMar 9, 2020D35,275
Stuart IainOfficer — Chief Scientific OfficerMar 9, 2020D12,333
Schwartz AharonDirectorMar 9, 2020D112,200
Kazanchyan AnnaDirectorMar 9, 2020D15,714
Hirsch StanleyDirectorMar 9, 2020D52,842
Harsch MutyaOfficer — CLO and General CounselMar 9, 2020D12,742
Hadar IlanOfficer — CFO &amp; Country ManagerMar 9, 2020D14,077
Domzalski DavidOfficer — CEOMar 9, 2020D90,902
Bruno Anthony DDirectorMar 9, 2020D62,647

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.